Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
analgesics	4283	175591-09-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tapentadol tapentadol hydrochloride nucynta tapentadol HCl	An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES. Molecular weight: 221.34 Formula: C14H23NO CLOGP: 3.15 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -2.45 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tapentadol
tapentadol hydrochloride
nucynta
tapentadol HCl

An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.

Molecular weight: 221.34
Formula: C14H23NO
CLOGP: 3.15
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -2.45
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	4.64 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	21.33 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.39 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	1.16 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
BA (Bioavailability)	32 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,IGF1R,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	49
kinase-selectivity-class	ACVR2B,AXL,CAMK2D,CDK4,DDR1,EIF2AK3,EPHA2,EPHB4,FLT3,GAK,INSR,LCK,MAP3K7,MAP4K1,PDK4,SIK2,SIK3,TEK	18
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Nov. 20, 2008	FDA	JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	168.05	15.35	228	15595	287618	90325006
Drug interaction	149.36	15.35	211	15612	276242	90336382
Serotonin syndrome	138.84	15.35	85	15738	37802	90574822
Sopor	132.49	15.35	71	15752	24573	90588051
Paroxysmal extreme pain disorder	89.46	15.35	16	15807	110	90612514
Miosis	89.09	15.35	40	15783	9444	90603180
Chronic respiratory disease	87.12	15.35	18	15805	283	90612341
Degenerative bone disease	82.06	15.35	17	15806	271	90612353
Confusional arousal	80.86	15.35	17	15806	292	90612332
Drug abuse	80.58	15.35	85	15738	82262	90530362
Completed suicide	78.58	15.35	111	15712	144947	90467677
Post cholecystectomy syndrome	77.52	15.35	20	15803	861	90611763
Post procedural hypothyroidism	77.23	15.35	17	15806	366	90612258
HIV infection	73.02	15.35	17	15806	474	90612150
Electric shock	72.76	15.35	22	15801	1700	90610924
Agitation	72.40	15.35	73	15750	67025	90545599
Somnolence	69.36	15.35	128	15695	208956	90403668
Blood immunoglobulin A increased	65.61	15.35	19	15804	1264	90611360
Respiratory depression	64.97	15.35	38	15785	15537	90597087
Vitamin B12 increased	63.11	15.35	20	15803	1806	90610818
Granulocyte count increased	62.25	15.35	19	15804	1515	90611109
Delirium	61.21	15.35	83	15740	104276	90508348
Glomerular filtration rate increased	60.74	15.35	20	15803	2040	90610584
Polymyalgia rheumatica	59.87	15.35	25	15798	4952	90607672
Mouth injury	58.18	15.35	17	15806	1167	90611457
Rheumatoid factor increased	57.65	15.35	20	15803	2391	90610233
Abdominal discomfort	52.31	15.35	10	15813	477318	90135306
Post-traumatic stress disorder	52.29	15.35	25	15798	6803	90605821
Suicide attempt	52.05	15.35	65	15758	75334	90537290
Intervertebral discitis	52.02	15.35	22	15801	4498	90608126
Dactylitis	51.84	15.35	21	15802	3852	90608772
Aspartate aminotransferase	51.64	15.35	14	15809	731	90611893
Systemic lupus erythematosus	51.16	15.35	3	15820	361893	90250731
Intentional overdose	51.07	15.35	72	15751	93762	90518862
Hyperhidrosis	51.01	15.35	88	15735	136217	90476407
Tremor	48.55	15.35	92	15731	153081	90459543
Vitamin D deficiency	48.52	15.35	33	15790	17523	90595101
Overdose	46.65	15.35	92	15731	157617	90455007
Restlessness	46.30	15.35	43	15780	35677	90576947
Throat clearing	45.19	15.35	19	15804	3828	90608796
Hallucination	44.15	15.35	56	15767	65903	90546721
Tongue discomfort	44.04	15.35	17	15806	2748	90609876
Hyperthermia malignant	43.96	15.35	14	15809	1284	90611340
Blood uric acid increased	43.66	15.35	23	15800	7681	90604943
Abnormal dreams	43.13	15.35	26	15797	11231	90601393
Multiple sclerosis	42.99	15.35	37	15786	27803	90584821
Joint noise	42.44	15.35	20	15803	5270	90607354
Reflexes abnormal	42.05	15.35	12	15811	757	90611867
Disorientation	40.42	15.35	44	15779	44070	90568554
Hypertensive crisis	38.92	15.35	29	15794	17755	90594869
Wound	38.65	15.35	4	15819	302976	90309648
Vitamin B12 deficiency	38.63	15.35	21	15802	7465	90605159
Unresponsive to stimuli	38.43	15.35	40	15783	38081	90574543
Monocyte count increased	37.43	15.35	22	15801	9075	90603549
Arthropathy	37.39	15.35	9	15814	366233	90246391
Spinal disorder	37.23	15.35	24	15799	11655	90600969
Joint swelling	36.96	15.35	21	15802	503279	90109345
Mydriasis	36.30	15.35	26	15797	14986	90597638
Breast cancer metastatic	36.11	15.35	26	15797	15106	90597518
Loss of consciousness	35.80	15.35	77	15746	140161	90472463
White blood cells urine positive	35.69	15.35	19	15804	6479	90606145
Sepsis neonatal	35.48	15.35	10	15813	603	90612021
Syncope	35.20	15.35	74	15749	132589	90480035
Amnestic disorder	34.45	15.35	9	15814	407	90612217
Cholecystitis acute	34.18	15.35	21	15802	9383	90603241
Depressed level of consciousness	34.03	15.35	52	15771	72732	90539892
Embolism venous	33.14	15.35	15	15808	3605	90609019
Progressive multifocal leukoencephalopathy	33.08	15.35	25	15798	15630	90596994
Peptic ulcer	32.90	15.35	17	15806	5458	90607166
Confusional state	32.87	15.35	144	15679	386061	90226563
Hepatic enzyme increased	32.87	15.35	11	15812	360725	90251899
Maternal exposure during pregnancy	32.78	15.35	11	15812	360052	90252572
Seizure	32.50	15.35	78	15745	152551	90460073
Suicidal ideation	32.07	15.35	51	15772	73804	90538820
Blood pressure systolic decreased	31.91	15.35	20	15803	9250	90603374
Demyelination	31.70	15.35	19	15804	8121	90604503
Accidental exposure to product by child	31.65	15.35	11	15812	1322	90611302
Chemical burn of oral cavity	30.94	15.35	6	15817	67	90612557
Blister	30.93	15.35	4	15819	254994	90357630
Short-bowel syndrome	30.10	15.35	9	15814	669	90611955
Off label use	29.28	15.35	97	15726	1102155	89510469
Application site injury	29.15	15.35	5	15818	26	90612598
Aspartate aminotransferase abnormal	27.54	15.35	12	15811	2637	90609987
Cognitive disorder	27.52	15.35	46	15777	69361	90543263
Temperature intolerance	27.18	15.35	20	15803	12010	90600614
Bundle branch block left	27.12	15.35	17	15806	7868	90604756
Withdrawal syndrome	27.06	15.35	26	15797	22498	90590126
Eyelid skin dryness	27.01	15.35	8	15815	576	90612048
Osteopenia	26.60	15.35	26	15797	22976	90589648
Constipation	26.52	15.35	108	15715	280287	90332337
Allodynia	26.45	15.35	9	15814	1015	90611609
Drug screen negative	26.41	15.35	7	15816	335	90612289
Swelling	26.04	15.35	21	15802	419037	90193587
Renal cell carcinoma stage I	25.94	15.35	5	15818	54	90612570
Irritable bowel syndrome	25.78	15.35	3	15820	207445	90405179
Drug withdrawal syndrome neonatal	25.73	15.35	11	15812	2308	90610316
Malignant neoplasm progression	25.36	15.35	57	15766	106813	90505811
Middle insomnia	25.33	15.35	22	15801	16729	90595895
Gingivitis	24.44	15.35	17	15806	9352	90603272
Blood glucose decreased	24.36	15.35	25	15798	23404	90589220
Clubbing	23.78	15.35	7	15816	493	90612131
Depressed mood	23.64	15.35	36	15787	50186	90562438
Drug screen positive	23.54	15.35	12	15811	3745	90608879
Blood cholesterol increased	23.53	15.35	4	15819	208008	90404616
Application site ulcer	23.51	15.35	5	15818	91	90612533
Hypoglycaemia	23.41	15.35	43	15780	69805	90542819
Dyslipidaemia	23.28	15.35	17	15806	10090	90602534
Opiates negative	22.96	15.35	3	15820	0	90612624
Glycosylated haemoglobin increased	22.65	15.35	20	15803	15542	90597082
Gaze palsy	22.31	15.35	9	15814	1632	90610992
Nasal polyps	22.16	15.35	17	15806	10863	90601761
Nausea	21.78	15.35	292	15531	1110024	89502600
Infection	21.44	15.35	19	15804	362075	90250549
Disturbance in attention	21.09	15.35	33	15790	47076	90565548
Logorrhoea	20.93	15.35	10	15813	2717	90609907
Product prescribing error	20.81	15.35	26	15797	30119	90582505
Neutrophil count increased	20.72	15.35	21	15802	19369	90593255
Blood urea increased	20.63	15.35	26	15797	30387	90582237
Urinary retention	20.58	15.35	29	15794	37715	90574909
Bradyphrenia	20.30	15.35	14	15809	7598	90605026
Cardio-respiratory arrest	20.07	15.35	38	15785	63102	90549522
Labelled drug-drug interaction medication error	19.76	15.35	18	15805	14564	90598060
Therapeutic product effect decreased	19.75	15.35	12	15811	277559	90335065
Pharyngeal enanthema	19.73	15.35	4	15819	57	90612567
Synovectomy	19.34	15.35	5	15818	217	90612407
Thoracic vertebral fracture	19.32	15.35	12	15811	5462	90607162
Concomitant disease aggravated	19.20	15.35	16	15807	11502	90601122
Hyperresponsive to stimuli	19.18	15.35	4	15819	66	90612558
Psoriatic arthropathy	19.05	15.35	8	15815	228327	90384297
Coordination abnormal	19.04	15.35	21	15802	21335	90591289
Tinnitus	19.03	15.35	30	15793	43072	90569552
Myoclonic epilepsy	18.99	15.35	8	15815	1619	90611005
Pneumonia aspiration	18.78	15.35	29	15794	40911	90571713
Lymphoedema	18.68	15.35	17	15806	13736	90598888
Tachycardia	18.42	15.35	65	15758	157608	90455016
Presyncope	18.18	15.35	25	15798	31780	90580844
Alopecia	18.12	15.35	37	15786	495034	90117590
Liver injury	17.77	15.35	4	15819	170563	90442061
Bacteriuria	17.74	15.35	7	15816	1199	90611425
Small intestinal resection	17.67	15.35	6	15817	672	90611952
Blood test abnormal	17.64	15.35	20	15803	20932	90591692
Lower respiratory tract infection	17.61	15.35	11	15812	250648	90361976
Ulcer	17.53	15.35	25	15798	32857	90579767
Hypersensitivity	17.49	15.35	33	15790	454644	90157980
Nervous system disorder	17.15	15.35	20	15803	21573	90591051
Infusion related reaction	17.15	15.35	29	15794	416751	90195873
Pneumonia	16.98	15.35	56	15767	638003	89974621
Dyskinesia	16.93	15.35	26	15797	36508	90576116
Aortic valve stenosis	16.78	15.35	10	15813	4230	90608394
Treatment failure	16.75	15.35	17	15806	303911	90308713
Total bile acids increased	16.62	15.35	4	15819	129	90612495
Sedation	16.58	15.35	30	15793	48141	90564483
Contraindicated product administered	16.44	15.35	19	15804	320120	90292504
Lumbar vertebral fracture	15.96	15.35	12	15811	7446	90605178
Rhinitis allergic	15.82	15.35	17	15806	16768	90595856
Drug screen false positive	15.74	15.35	6	15817	937	90611687
Discomfort	15.52	15.35	15	15808	274320	90338304
Rash	15.47	15.35	79	15744	796021	89816603
Product use issue	15.45	15.35	21	15802	329898	90282726
Anal hypoaesthesia	15.43	15.35	3	15820	34	90612590

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serotonin syndrome	148.34	19.21	81	8339	25764	42587151
Delirium	137.43	19.21	100	8320	52419	42560496
Toxicity to various agents	131.99	19.21	192	8228	228944	42383971
Drug abuse	128.44	19.21	129	8291	104642	42508273
Quality of life decreased	117.31	19.21	43	8377	5333	42607582
Hyperaesthesia	116.66	19.21	44	8376	5908	42607007
Constipation	111.24	19.21	148	8272	162143	42450772
Allodynia	75.35	19.21	21	8399	1073	42611842
Drug dependence	72.86	19.21	54	8366	29040	42583875
Polyneuropathy in malignant disease	70.05	19.21	16	8404	360	42612555
Overdose	61.47	19.21	89	8331	105175	42507740
Confusional state	59.21	19.21	113	8307	167484	42445431
Sopor	58.56	19.21	35	8385	13167	42599748
Suicide attempt	53.14	19.21	55	8365	46045	42566870
Intentional overdose	51.57	19.21	57	8363	51399	42561516
Congenital megacolon	42.35	19.21	8	8412	67	42612848
Hallucination	40.09	19.21	53	8367	57454	42555461
Respiratory syncytial virus bronchitis	39.51	19.21	8	8412	99	42612816
Drug interaction	39.46	19.21	129	8291	266870	42346045
Somnolence	38.96	19.21	86	8334	141019	42471896
Withdrawal syndrome	38.27	19.21	28	8392	14747	42598168
Sleep deficit	37.98	19.21	12	8408	947	42611968
Testicular seminoma (pure)	34.18	19.21	8	8412	201	42612714
Loss of consciousness	32.20	19.21	62	8358	92292	42520623
Dysaesthesia	29.74	19.21	13	8407	2544	42610371
Xanthelasma	28.63	19.21	6	8414	89	42612826
Respiratory depression	28.26	19.21	26	8394	18842	42594073
Urinary retention	28.02	19.21	38	8382	42176	42570739
Malignant neoplasm progression	27.59	19.21	64	8356	108336	42504579
Application site hypersensitivity	27.48	19.21	6	8414	109	42612806
Metastases to bone	27.38	19.21	23	8397	14786	42598129
Post herpetic neuralgia	27.30	19.21	10	8410	1236	42611679
Drug screen positive	26.62	19.21	14	8406	4117	42608798
Drug withdrawal syndrome	25.33	19.21	26	8394	21523	42591392
Application site pain	24.38	19.21	11	8409	2318	42610597
Dermatitis allergic	24.08	19.21	17	8403	8466	42604449
Metastases to lung	23.75	19.21	19	8401	11405	42601510
Application site erythema	23.36	19.21	11	8409	2555	42610360
Adverse event	23.34	19.21	26	8394	23614	42589301
Poor feeding infant	23.16	19.21	8	8412	834	42612081
Tremor	22.26	19.21	55	8365	96874	42516041
Accidental exposure to product by child	21.64	19.21	9	8411	1558	42611357
Disorientation	21.53	19.21	31	8389	36358	42576557
Nausea	21	19.21	142	8278	396657	42216258
Reaction to excipient	21.00	19.21	7	8413	655	42612260
Pharyngeal inflammation	20.89	19.21	7	8413	665	42612250
Myofascial pain syndrome	20.57	19.21	6	8414	361	42612554
Depression	20.30	19.21	58	8362	111305	42501610
Sedation	19.57	19.21	27	8393	30448	42582467

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	267.31	15.03	384	20183	480171	110088561
Drug abuse	205.02	15.03	206	20361	177205	110391527
Serotonin syndrome	187.68	15.03	124	20443	59029	110509703
Sopor	173.19	15.03	99	20468	36447	110532285
Drug interaction	147.72	15.03	302	20265	499881	110068851
Delirium	129.46	15.03	142	20425	134883	110433849
Hyperaesthesia	103.87	15.03	52	20515	14675	110554057
Allodynia	100.89	15.03	30	20537	2053	110566679
Suicide attempt	90.95	15.03	104	20463	103290	110465442
Constipation	90.42	15.03	203	20364	357583	110211149
Respiratory depression	89.33	15.03	62	20505	31939	110536793
Somnolence	86.89	15.03	179	20388	297270	110271462
Intentional overdose	85.46	15.03	114	20453	132387	110436345
Miosis	84.39	15.03	52	20515	21931	110546801
Quality of life decreased	82.55	15.03	44	20523	14125	110554607
Overdose	79.51	15.03	150	20417	233644	110335088
Confusional state	73.15	15.03	222	20345	468458	110100274
Accidental exposure to product by child	72.83	15.03	26	20541	3172	110565560
Post cholecystectomy syndrome	72.12	15.03	19	20548	833	110567899
Polyneuropathy in malignant disease	66.43	15.03	16	20551	485	110568247
Completed suicide	66.25	15.03	142	20425	242239	110326493
Disorientation	65.39	15.03	73	20494	70598	110498134
Loss of consciousness	63.09	15.03	123	20444	196183	110372549
Drug dependence	63.08	15.03	61	20506	49959	110518773
Tremor	61.73	15.03	124	20443	202108	110366624
Electric shock	57.79	15.03	19	20548	1809	110566923
Glomerular filtration rate increased	56.64	15.03	19	20548	1926	110566806
Blood immunoglobulin A increased	56.51	15.03	18	20549	1550	110567182
Agitation	56.27	15.03	86	20481	112965	110455767
Vitamin B12 increased	55.61	15.03	19	20548	2036	110566696
Granulocyte count increased	52.36	15.03	18	20549	1965	110566767
Rheumatoid factor increased	51.93	15.03	19	20548	2486	110566246
Post-traumatic stress disorder	48.61	15.03	24	20543	6572	110562160
Restlessness	48.46	15.03	56	20511	56203	110512529
Malignant neoplasm progression	47.35	15.03	102	20465	174465	110394267
Aspartate aminotransferase	47.12	15.03	14	20553	955	110567777
Hyperhidrosis	46.92	15.03	106	20461	187192	110381540
Dactylitis	45.96	15.03	20	20547	4113	110564619
Sepsis neonatal	45.80	15.03	9	20558	101	110568631
Vitamin D deficiency	44.99	15.03	33	20534	18519	110550213
Intervertebral discitis	41.54	15.03	22	20545	6968	110561764
Hallucination	39.41	15.03	69	20498	101363	110467369
Joint noise	38.75	15.03	19	20548	5124	110563608
Throat clearing	38.73	15.03	18	20549	4315	110564417
Depressed level of consciousness	38.07	15.03	72	20495	112206	110456526
Reflexes abnormal	37.65	15.03	12	20555	1035	110567697
Drug screen positive	37.60	15.03	20	20547	6390	110562342
Multiple sclerosis	37.51	15.03	34	20533	25664	110543068
Nausea	37.48	15.03	372	20195	1235318	109333414
Joint swelling	37.09	15.03	18	20549	442827	110125905
Off label use	36.95	15.03	149	20418	1500036	109068696
Testicular seminoma (pure)	36.21	15.03	8	20559	164	110568568
Withdrawal syndrome	35.36	15.03	36	20531	31344	110537388
Application site pain	34.65	15.03	18	20549	5481	110563251
Application site erythema	34.31	15.03	18	20549	5592	110563140
Temperature intolerance	34.25	15.03	25	20542	13925	110554807
Spinal disorder	33.37	15.03	23	20544	11705	110557027
Hypertensive crisis	33.15	15.03	31	20536	24341	110544391
Unresponsive to stimuli	32.40	15.03	49	20518	63741	110504991
White blood cells urine positive	31.97	15.03	19	20548	7505	110561227
Sleep deficit	31.34	15.03	12	20555	1780	110566952
Maternal exposure during pregnancy	31.20	15.03	5	20562	254878	110313854
Drug withdrawal syndrome neonatal	30.67	15.03	8	20559	337	110568395
Vitamin B12 deficiency	29.27	15.03	20	20547	10035	110558697
Sedation	29.16	15.03	49	20518	69634	110499098
Application site injury	29.00	15.03	5	20562	25	110568707
Pneumonia aspiration	28.66	15.03	53	20514	81180	110487552
Amnestic disorder	28.65	15.03	9	20558	741	110567991
Hepatic enzyme increased	28.49	15.03	12	20555	320880	110247852
Short-bowel syndrome	28.34	15.03	9	20558	767	110567965
Hyperthermia malignant	28.17	15.03	14	20553	3886	110564846
Mydriasis	27.89	15.03	27	20540	22130	110546602
Alopecia	27.37	15.03	17	20550	364736	110203996
Abdominal discomfort	27.36	15.03	20	20547	393838	110174894
Disturbance in attention	26.48	15.03	44	20523	61951	110506781
Monocyte count increased	26.41	15.03	21	20546	13272	110555460
Syncope	26.13	15.03	90	20477	202446	110366286
Demyelination	25.68	15.03	18	20549	9411	110559321
Xanthelasma	25.54	15.03	6	20561	163	110568569
Eyelid skin dryness	24.98	15.03	8	20559	701	110568031
Drug withdrawal syndrome	24.90	15.03	33	20534	38021	110530711
Pharyngeal inflammation	24.78	15.03	10	20557	1704	110567028
Chemical burn of oral cavity	24.63	15.03	5	20562	67	110568665
Infection	24.37	15.03	19	20548	362181	110206551
Aspartate aminotransferase abnormal	24.21	15.03	12	20555	3313	110565419
Blood cholesterol increased	24.07	15.03	3	20564	184782	110383950
Seizure	24.06	15.03	93	20474	221092	110347640
Hallucination, visual	23.87	15.03	33	20534	39572	110529160
Hypersensitivity	23.81	15.03	24	20543	403974	110164758
Arthropathy	23.58	15.03	12	20555	287510	110281222
Renal cell carcinoma stage I	23.57	15.03	5	20562	84	110568648
False positive investigation result	23.06	15.03	9	20558	1405	110567327
Blood pressure systolic decreased	22.04	15.03	19	20548	13422	110555310
Wheezing	21.93	15.03	10	20557	255220	110313512
Application site ulcer	21.84	15.03	5	20562	121	110568611
Psoriatic arthropathy	21.67	15.03	5	20562	196756	110371976
Urinary retention	21.56	15.03	43	20524	69640	110499092
Cholecystitis acute	21.32	15.03	20	20547	15762	110552970
Exposure during pregnancy	21.14	15.03	3	20564	167421	110401311
Benign prostatic hyperplasia	20.69	15.03	21	20546	18213	110550519
Dysphagia	20.46	15.03	69	20498	153531	110415201
Psychomotor skills impaired	20.46	15.03	14	20553	7044	110561688
Micturition disorder	20.32	15.03	12	20555	4686	110564046
Cognitive disorder	20.22	15.03	48	20519	87463	110481269
Progressive multifocal leukoencephalopathy	20.08	15.03	24	20543	24932	110543800
Clubbing	20.07	15.03	7	20560	798	110567934
Product prescribing error	20.03	15.03	35	20532	51296	110517436
Anal hypoaesthesia	19.81	15.03	4	20563	52	110568680
Blood uric acid increased	19.50	15.03	22	20545	21507	110547225
Swelling	19.40	15.03	22	20545	351019	110217713
Depressed mood	19.38	15.03	38	20529	60771	110507961
Hyperresponsive to stimuli	19.28	15.03	4	20563	60	110568672
Substance abuse	19.20	15.03	17	20550	12446	110556286
Ulcer	18.95	15.03	31	20536	43085	110525647
Thoracic vertebral fracture	18.81	15.03	13	20554	6642	110562090
Pharyngeal enanthema	18.70	15.03	4	20563	70	110568662
Metastases to bone	18.70	15.03	26	20541	31346	110537386
Lower respiratory tract infection	18.69	15.03	11	20556	243095	110325637
Dysaesthesia	18.48	15.03	13	20554	6834	110561898
Irritable bowel syndrome	18.43	15.03	4	20563	164211	110404521
Blood glucose decreased	18.42	15.03	25	20542	29463	110539269
Synovectomy	18.11	15.03	5	20562	262	110568470
Bradyphrenia	18.07	15.03	16	20551	11712	110557020
Impaired healing	18.03	15.03	7	20560	196710	110372022
Psychomotor hyperactivity	17.15	15.03	20	20547	20257	110548475
Embolism venous	17.06	15.03	11	20556	5012	110563720
Accident	16.99	15.03	15	20552	10937	110557795
Cachexia	16.65	15.03	16	20551	12989	110555743
Vertigo	16.26	15.03	44	20523	86826	110481906
Bacteriuria	16.12	15.03	7	20560	1431	110567301
Dermatitis allergic	16.04	15.03	20	20547	21704	110547028
Weight increased	15.84	15.03	34	20533	419610	110149122
Post herpetic neuralgia	15.78	15.03	9	20558	3292	110565440
Clonus	15.69	15.03	13	20554	8703	110560029
Asthenia	15.55	15.03	196	20371	688803	109879929
Gaze palsy	15.52	15.03	9	20558	3398	110565334
Intestinal obstruction	15.46	15.03	32	20535	53195	110515537
Spinal fracture	15.38	15.03	20	20547	22613	110546119
Blister	15.19	15.03	12	20555	227364	110341368
Coordination abnormal	15.17	15.03	21	20546	25207	110543525
Metastases to lung	15.09	15.03	20	20547	23043	110545689
Suicidal ideation	15.07	15.03	45	20522	93892	110474840

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02AX06	NERVOUS SYSTEM ANALGESICS OPIOIDS Other opioids
FDA MoA	N0000000174	Opioid Agonists
MeSH PA	D000700	Analgesics
MeSH PA	D000701	Analgesics, Opioid
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D009294	Narcotics
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
FDA EPC	N0000175690	Opioid Agonist
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:67079	anti-inflammatory agent

Related Drugs by ATC class:

N02AX Other opioids 6 drugs

dezocine meptazinol naloxone oliceridine tilidine tramadol

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pain	indication	22253000
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Asthenia	contraindication	13791008
Alcohol intoxication	contraindication	25702006
Hypercapnia	contraindication	29596007
Myxedema	contraindication	43153006	DOID:11634
Paralytic ileus	contraindication	55525008	DOID:8442
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Sleep apnea	contraindication	73430006	DOID:0050847
Pancreatitis	contraindication	75694006	DOID:4989
Decreased respiratory function	contraindication	80954004
Injury of head	contraindication	82271004
Cor pulmonale	contraindication	83291003	DOID:8515
Disorder of biliary tract	contraindication	105997008	DOID:9741
Seizure disorder	contraindication	128613002
Disease of liver	contraindication	235856003	DOID:409
Morbid obesity	contraindication	238136002	DOID:11981
Exacerbation of asthma	contraindication	281239006
Lesion of brain	contraindication	301766008
Coma	contraindication	371632003
Hypoxia	contraindication	389086002
Central nervous system depression	contraindication	418072004
Acute exacerbation of asthma	contraindication	708038006
Kyphoscoliosis with Respiratory Compromise	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.76	acidic
pKa2	9.12	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 100MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
EQ 100MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
EQ 150MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
EQ 150MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
EQ 200MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
EQ 200MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
EQ 250MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
EQ 250MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
EQ 50MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
EQ 50MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	11344512	April 21, 2028	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
EQ 100MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	8536130	Sept. 22, 2028	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
EQ 150MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	8536130	Sept. 22, 2028	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
EQ 200MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	8536130	Sept. 22, 2028	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
EQ 250MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	8536130	Sept. 22, 2028	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
EQ 50MG BASE	NUCYNTA ER	COLLEGIUM PHARM INC	N200533	Aug. 25, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	8536130	Sept. 22, 2028	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 100MG BASE	NUCYNTA	COLLEGIUM PHARM INC	N022304	Nov. 20, 2008	RX	TABLET	ORAL	July 3, 2026	NEW PATIENT POPULATION
EQ 50MG BASE	NUCYNTA	COLLEGIUM PHARM INC	N022304	Nov. 20, 2008	RX	TABLET	ORAL	July 3, 2026	NEW PATIENT POPULATION
EQ 75MG BASE	NUCYNTA	COLLEGIUM PHARM INC	N022304	Nov. 20, 2008	RX	TABLET	ORAL	July 3, 2026	NEW PATIENT POPULATION
EQ 20MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	NUCYNTA	COLLEGIUM PHARM INC	N203794	Oct. 15, 2012	DISCN	SOLUTION	ORAL	July 3, 2026	NEW PATIENT POPULATION
EQ 100MG BASE	NUCYNTA	COLLEGIUM PHARM INC	N022304	Nov. 20, 2008	RX	TABLET	ORAL	Jan. 3, 2027	PEDIATRIC EXCLUSIVITY
EQ 50MG BASE	NUCYNTA	COLLEGIUM PHARM INC	N022304	Nov. 20, 2008	RX	TABLET	ORAL	Jan. 3, 2027	PEDIATRIC EXCLUSIVITY
EQ 75MG BASE	NUCYNTA	COLLEGIUM PHARM INC	N022304	Nov. 20, 2008	RX	TABLET	ORAL	Jan. 3, 2027	PEDIATRIC EXCLUSIVITY
EQ 20MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	NUCYNTA	COLLEGIUM PHARM INC	N203794	Oct. 15, 2012	DISCN	SOLUTION	ORAL	Jan. 3, 2027	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	AGONIST	Ki	7.02	WOMBAT-PK	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	6.32	WOMBAT-PK	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.66	CHEMBL

External reference:

ID	Source
4029061	VUID
N0000179820	NUI
D06007	KEGG_DRUG
175591-23-8	SECONDARY_CAS_RN
4029061	VANDF
4029062	VANDF
C2001271	UMLSCUI
CHEBI:135935	CHEBI
CHEMBL1201776	ChEMBL_ID
CHEMBL1201777	ChEMBL_ID
D000077432	MESH_DESCRIPTOR_UI
DB06204	DRUGBANK_ID
7477	IUPHAR_LIGAND_ID
8216	INN_ID
H8A007M585	UNII
9838022	PUBCHEM_CID
787390	RXNORM
165888	MMSL
26545	MMSL
303726	MMSL
35753	MMSL
d07453	MMSL
013168	NDDF
013169	NDDF
441757005	SNOMEDCT_US
442004000	SNOMEDCT_US
442699004	SNOMEDCT_US
H8A007M585	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0936	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	NDA authorized generic	39 sections
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0937	TABLET, FILM COATED, EXTENDED RELEASE	100 mg	ORAL	NDA authorized generic	39 sections
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0938	TABLET, FILM COATED, EXTENDED RELEASE	150 mg	ORAL	NDA authorized generic	39 sections
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0939	TABLET, FILM COATED, EXTENDED RELEASE	200 mg	ORAL	NDA authorized generic	39 sections
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0940	TABLET, FILM COATED, EXTENDED RELEASE	250 mg	ORAL	NDA authorized generic	39 sections
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0942	TABLET, FILM COATED	50 mg	ORAL	NDA authorized generic	39 sections
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0943	TABLET, FILM COATED	75 mg	ORAL	NDA authorized generic	39 sections
TAPENTADOL	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0945	TABLET, FILM COATED	100 mg	ORAL	NDA authorized generic	39 sections
NUCYNTA	HUMAN PRESCRIPTION DRUG LABEL	1	16590-289	TABLET, FILM COATED	100 mg	ORAL	NDA	35 sections
NUCYNTA	HUMAN PRESCRIPTION DRUG LABEL	1	16590-863	TABLET, FILM COATED	50 mg	ORAL	NDA	35 sections
NUCYNTA	HUMAN PRESCRIPTION DRUG LABEL	1	16590-889	TABLET, FILM COATED	75 mg	ORAL	NDA	32 sections
NUCYNTA	HUMAN PRESCRIPTION DRUG LABEL	1	21695-069	TABLET, FILM COATED	50 mg	ORAL	NDA	34 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	24510-050	TABLET, FILM COATED	50 mg	ORAL	NDA	39 sections
NucyntaER	HUMAN PRESCRIPTION DRUG LABEL	1	24510-058	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	NDA	39 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	24510-075	TABLET, FILM COATED	75 mg	ORAL	NDA	39 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	24510-100	TABLET, FILM COATED	100 mg	ORAL	NDA	39 sections
NucyntaER	HUMAN PRESCRIPTION DRUG LABEL	1	24510-116	TABLET, FILM COATED, EXTENDED RELEASE	100 mg	ORAL	NDA	39 sections
NucyntaER	HUMAN PRESCRIPTION DRUG LABEL	1	24510-174	TABLET, FILM COATED, EXTENDED RELEASE	150 mg	ORAL	NDA	39 sections
NucyntaER	HUMAN PRESCRIPTION DRUG LABEL	1	24510-232	TABLET, FILM COATED, EXTENDED RELEASE	200 mg	ORAL	NDA	39 sections
NucyntaER	HUMAN PRESCRIPTION DRUG LABEL	1	24510-291	TABLET, FILM COATED, EXTENDED RELEASE	250 mg	ORAL	NDA	39 sections
Tapentadol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-626	TABLET, FILM COATED	50 mg	ORAL	ANDA	34 sections
Tapentadol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-627	TABLET, FILM COATED	75 mg	ORAL	ANDA	34 sections
Tapentadol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-628	TABLET, FILM COATED	100 mg	ORAL	ANDA	34 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5979	TABLET, FILM COATED	50 mg	ORAL	NDA	33 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6002	TABLET, FILM COATED	75 mg	ORAL	NDA	33 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6039	TABLET, FILM COATED	100 mg	ORAL	NDA	33 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	69865-210	TABLET, FILM COATED	50 mg	ORAL	NDA	37 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	69865-220	TABLET, FILM COATED	75 mg	ORAL	NDA	37 sections
Nucynta	HUMAN PRESCRIPTION DRUG LABEL	1	69865-230	TABLET, FILM COATED	100 mg	ORAL	NDA	37 sections
NucyntaER	HUMAN PRESCRIPTION DRUG LABEL	1	69865-240	TABLET, FILM COATED, EXTENDED RELEASE	50 mg	ORAL	NDA	38 sections

Ask DrugCentral

Try a sample question

tapentadol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: